Drugs / thrombopoietin
thrombopoietin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT04089267 | Dec 2016 → Dec 2018 | autoimmune thrombocytopenic purpura | Shenyang Sunshine Pharmaceutical Co., LTD. | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1/2 | NCT00006225 Background | Nov 1999 → Jan 2004 | breast cancer, leukemia, myelodysplastic/myeloproliferative disease, plasma cell neoplasm | Northwestern University | Completed | No outcome recorded |
| Phase 2/3 | NCT02241031 Comparator | Sep 2014 → Sep 2016 | thrombocytopenia | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| — | NCT00038012 Background | Jul 1999 → Jun 2004 | female reproductive system neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | thrombopoietin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02241031 ↗ |
| Known as | rhTPO | “different recombinant human thrombopoietin (rhTPO) regimens” NCT04089267 ↗ |
| Known as | TPO | “Platelet stimulating factors include thrombopoietin (TPO) and interleukin-11 and so on.” NCT02241031 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human thrombopoietin” NCT00006225 ↗ |
| Route | Other | “rhTPO injection” NCT04089267 ↗ |